Arch Therapeutics Inc


Prices are adjusted according to historical splits.

Arch Therapeutics Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$3.98 million
Book Value:
Revenue TTM:
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Arch Therapeutics Inc had its IPO on under the ticker symbol ARTH.

The company operates in the Healthcare sector and Biotechnology industry. Arch Therapeutics Inc has a staff strength of 8 employees.

Stock update

Shares of Arch Therapeutics Inc opened at $3.1 at the start of the last trading session i.e. 2023-05-27.

The stocks traded within a range of $3.1 - $3.1, and closed at $3.1.

This is a +11.11% increase from the previous day's closing price.

A total volume of 100 shares were traded at the close of the day’s session.

In the last one week, shares of Arch Therapeutics Inc have increased by +3.33%.

Arch Therapeutics Inc's Key Ratios

Arch Therapeutics Inc has a market cap of $3.98 million, indicating a price to book ratio of 34.6063 and a price to sales ratio of 638.6455.

In the last 12-months Arch Therapeutics Inc’s revenue was $17217 with a gross profit of $-35837 and an EBITDA of $-5471671. The EBITDA ratio measures Arch Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Arch Therapeutics Inc’s operating margin was 0% while its return on assets stood at -160.65% with a return of equity of -4014.8%.

In Q1, Arch Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 33.3%.

Arch Therapeutics Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-3.84 per share while it has a forward price to earnings multiple of 1.4667 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Arch Therapeutics Inc’s profitability.

Arch Therapeutics Inc stock is trading at a EV to sales ratio of 801.227 and a EV to EBITDA ratio of -2.5134. Its price to sales ratio in the trailing 12-months stood at 638.6455.

Arch Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$1.59 million
Total Liabilities
$7.98 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Arch Therapeutics Inc ended 2023 with $1.59 million in total assets and $0 in total liabilities. Its intangible assets were valued at $1.59 million while shareholder equity stood at $-6386088.00.

Arch Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $7.98 million in other current liabilities, in common stock, $-57775306.00 in retained earnings and $0 in goodwill. Its cash balance stood at $29495.00 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.

Arch Therapeutics Inc’s total current assets stands at $1.59 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $2.43 million and inventory worth $1.40 million.

In 2023, Arch Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Arch Therapeutics Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Arch Therapeutics Inc stock is currently trading at $3.1 per share. It touched a 52-week high of $7 and a 52-week low of $7. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $3.17 and 200-day moving average was $1.78 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 1443.4% of the company’s stock are held by insiders while 0.6% are held by institutions.

Frequently Asked Questions About Arch Therapeutics Inc

The stock symbol (also called stock or share ticker) of Arch Therapeutics Inc is ARTH

The IPO of Arch Therapeutics Inc took place on

Similar Industry Stocks (Biotechnology)

Last Price

Most Active

Last Price
Tesla Inc (TSLA)

Top Gainers

Last Price
Boxed Inc (BOXD)

Top Losers

Last Price


Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.


235 Walnut Street, Framingham, MA, United States, 01702